Nexium Capsules LDA Specific Clinical Experience Investigation

AstraZeneca2,363 enrolled

Overview

The purpose of this investigation is to collect following data in patients given Nexium capsule (Nexium) for long term in usual-post-marketing therapy to prevention of recurrence of gastric ulcer or duodenal ulcer with Low dose Aspirin (LDA).

Nexium capsules Specific Clinical Experience Investigation for long-term use concerning prevention of recurrence of gastric ulcer or duodenal ulcer with Low dose Aspirin (LDA).

Study Type

OBSERVATIONAL

Enrollment

2,363

Conditions

Gastric Ulcer Duodenal Ulcer

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Exclusion Criteria: * Patients having gastric ulcer/duodenal ulcer when Nexium is started (Active phase (A1, A2) or healing phase (H1, H2) of Sakita-Miwa classification on endoscopy). * Patients who had been given Nexium for suppression of recurrence of gastric ulcer/duodenal ulcer.

Locations (47)

Outcomes

Primary Outcomes

Adverse events incidence

Number of Adverse Drug Reactions

Time frame: Up to 2 years

Secondary Outcomes

Non-recurrence rate of peptic ulcer

Time frame: Up to 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Research Site

Aichi, Japan

Research Site

Akita, Japan

Research Site

Aomori, Japan

Research Site

Chiba, Japan

Research Site

Ehime, Japan

Research Site

Fukui, Japan

Research Site

Fukuoka, Japan

Research Site

Fukushima, Japan

Research Site

Gifu, Japan

Research Site

Gunma, Japan

...and 37 more locations